Safety, Efficacy and Pharmacokinetics of Ritonavir 400mg/Saquinavir 400mg Twice Daily plus Rifampicin Combined Therapy in HIV Patients with Tuberculosis

被引：0
|
作者：
Valeria Cavalcanti Rolla
Maria A da Silva Vieira
Douglas Pereira Pinto
Maria C Lourenço
Carlos da Silva de Jesus
Mariza Gonçalves Morgado
Milton Ferreira Filho
Eduardo Werneck-Barroso
机构：
[1] Evandro Chagas Clinical Research Institute (IPEC),Reference Center of Tuberculosis
[2] Federal University of Rio de Janeiro,Thorax Diseases Institute
[3] IPEC,Pharmacokinetics Laboratory
[4] IPEC,Bacteriology Laboratory
[5] Oswaldo Cruz Institute,Laboratory of Immunology in HIV/AIDS
[6] Instituto de Pesquisa Clinica Evandro Chagas (IPEC),undefined
来源：
Clinical Drug Investigation | 2006年 / 26卷
关键词：
Tuberculosis; Viral Load; Rifampicin; Ritonavir; Saquinavir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To assess the drug concentrations, efficacy and safety of concomitant use of rifampicin and regimens containing ritonavir/saquinavir (400mg/400mg twice daily) in tuberculosis-HIV treatment-naive patients.
引用
收藏
页码：469 / 479
页数：10
相关论文
共 50 条
  • [1] Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis
    Rolla, Valeria Cavalcanti
    da Silva Vieira, Maria A.
    Pinto, Douglas Pereira
    Lourenco, Maria C.
    de Jesus, Carlos da Silva
    Morgado, Mariza Goncalves
    Ferreira Filho, Milton
    Werneck-Barroso, Eduardo
    CLINICAL DRUG INVESTIGATION, 2006, 26 (08) : 469 - 479
  • [2] Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients
    Moore, A.
    Sonecha, S.
    Boffito, M.
    Pozniak, A.
    Asboe, D.
    Barber, T.
    HIV MEDICINE, 2017, 18 : 3 - 3
  • [3] Efficacy, safety and pharmacokinetics of atazanavir (200 mg twice daily) plus raltegravir (400 mg twice daily) dual regimen in the clinical setting
    Marinaro, Letizia
    Calcagno, Andrea
    Ripamonti, Diego
    Cenderello, Giovanni
    Pirriatore, Veronica
    Trentini, Laura
    Salassa, Bernardino
    Bramato, Caterina
    Orofino, Giancarlo
    D'Avolio, Antonio
    Rizzi, Marco
    Di Perri, Giovanni
    Rusconi, Stefano
    Bonora, Stefano
    JOURNAL OF CLINICAL VIROLOGY, 2017, 87 : 30 - 36
  • [4] Pharmacokinetics, pharmacodynamics and pharmacogenomics of efavirenz 400mg once-daily during pregnancy and postpartum
    Lamorde, M.
    Wang, X.
    Neary, M.
    Bisdomini, E.
    Nakalema, S.
    Byakika, P.
    Mukonzo, J.
    Khan, W.
    Owen, A.
    McClure, M.
    Boffito, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2017, 20 : 122 - 122
  • [5] Clinical study of 400mg efavirenz treatment in newly diagnosed patients with HIV/AIDS
    Yang, Tongtong
    Zhou, Ruifeng
    He, Yuanhong
    Liu, Huanxia
    Guo, Zhihui
    Zhao, Xia
    Li, Taisheng
    He, Shenghua
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 37 (02) : 367 - 375
  • [6] Sorafenib in hepatocellular carcinoma (HCC): Is there a role for starting patients on a total daily dose of 400mg daily?
    Olowokure, Olugbenga Olanrele
    Singeltary, Brian
    Ghose, Abhimanyu
    Mierzwa, Michelle Lynn
    Latif, Tahir
    Shah, Shimul
    Ristagno, Ross
    Dwivedi, Alok Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [7] Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir 400 mg indinavir in HIV-infected patients
    Ghosn, J
    Lamotte, C
    Ait-Mohand, H
    Wirden, M
    Agher, R
    Schneider, L
    Bricaire, F
    Duvivier, C
    Calvez, V
    Peytavin, G
    Katlama, C
    AIDS, 2003, 17 (02) : 209 - 214
  • [8] Experience of a combination including indinavir 400 mg plus ritonavir 200 mg twice daily in HIV-infected patients: pharmacokinetic data
    Solas, C
    Petit, N
    Orticoni, M
    Durand, A
    Gastaut, JA
    Lacarelle, B
    PATHOLOGIE BIOLOGIE, 2002, 50 (09): : 565 - 567
  • [9] Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen
    Isaac, A
    Taylor, S
    Cane, P
    Smit, E
    Gihbons, SE
    White, DJ
    Drake, SM
    Khoo, S
    Back, DJ
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) : 498 - 502
  • [10] Dolutegravir 50mg thrice weekly plus atazanavir 400mg daily in a long-term virologically suppressed HIV-infected patient
    Lanzafame, Massimiliano
    Lattuada, Emanuela
    Nicole, Stefano
    Rigo, Fabio
    Cucchetto, Giulia
    Concia, Ercole
    Vento, Sandro
    INTERNATIONAL JOURNAL OF STD & AIDS, 2017, 28 (07) : 726 - 728
12345